Leptomeningeal Metastases Market Size was USD 1,700 million in 2024 and is Expected to grow immensely by 2034

The Leptomeningeal Metastases market size across the 7MM was valued at around USD 1,700 million in 2024 and is expected to grow throughout the forecast period from 2025 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Leptomeningeal Metastases landscape.

In 2024, within the EU4 and the UK, Germany recorded the largest Leptomeningeal Metastases market size at around USD 160 million, followed by the UK at approximately USD 130 million.

In 2024, there were approximately 300,000 incident cases of Leptomeningeal Metastases across the 7MM, highlighting a substantial clinical burden. According to DelveInsight’s analysis, the US had the highest share, representing around 40% of all incident cases in the 7MM that year.

In 2024, the US reported approximately 120,000 incident cases of Leptomeningeal Metastases, underscoring a significant disease burden and the urgent need for improved diagnostics and therapies. Across the EU4 and the UK, breast cancer accounted for the highest number of incident leptomeningeal metastases cases, with around 30,000 reported in 2024. In Germany, the 2024 cases were categorized by risk, with 66% of patients classified as “good risk” and 34% as “poor risk,” indicating a predominance of favorable prognostic profiles among the affected population.

DelveInsight’s report “Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Leptomeningeal Metastases landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the Leptomeningeal Metastases market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Leptomeningeal Metastases Market Forecast

Some of the key facts of the Leptomeningeal Metastases Market Report:  

• Key Leptomeningeal Metastases Companies: Biodexa Pharmaceuticals, Innovent Biologics (Suzhou) Co. Ltd., Plus Therapeutics, MedSIR, Quadriga Biosciences, Inc., Plus Therapeutics, Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others
• Key Leptomeningeal Metastases Therapies: MTD 217, Pemetrexed, 186RNL, Patritumab deruxtecan, QBS72S, REYOBIQ (Rhenium Re186 Obisbemeda), 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others
• Leptomeningeal metastasis is considered the third most common metastatic complication involving the central nervous system (CNS) 

Leptomeningeal Metastases Overview

Leptomeningeal Metastases occur when cancer cells spread to the leptomeninges, the thin membranes surrounding the brain and spinal cord. This condition is a rare but serious complication of advanced cancers, including breast cancer, lung cancer, and melanoma. LM can cause neurological symptoms such as headaches, nausea, vision problems, seizures, and weakness, depending on the areas affected. Diagnosis typically involves MRI imaging and cerebrospinal fluid analysis. Treatment options are limited and may include targeted therapies, radiation, or intrathecal chemotherapy to manage symptoms and slow disease progression.

Get a Free sample for the Leptomeningeal Metastases Market Report:

https://www.delveinsight.com/report-store/leptomeningeal-metastases-market

Key Trends in Leptomeningeal Metastases Therapeutics Market:

• Rise of Targeted Therapies and Immunotherapies: Increased development of EGFR inhibitors, HER2-targeted agents, and checkpoint inhibitors for improved CNS penetration.
• Focus on Personalized Medicine: Growing use of genomic profiling and biomarker-driven treatment strategies to tailor LM therapies.
• Advancements in Drug Delivery Systems: Development of intrathecal and nanoparticle-based drug delivery to overcome the blood-brain barrier.
• Integration of Combination Therapies: Emerging trend of combining systemic therapies with radiotherapy or intrathecal treatments for better efficacy.
• Expansion of Clinical Trials: Increasing number of global trials focusing on novel LM therapeutics to address unmet medical needs.

Leptomeningeal Metastases Epidemiology

The Leptomeningeal Metastases epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Leptomeningeal Metastases Epidemiology Segmentation:

The Leptomeningeal Metastases market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Different Cancer Types Associated with Leptomeningeal Metastases in the 7MM
• Total Diagnosed Cases of Leptomeningeal Metastases in the 7MM
• Total Cancer-specific Cases of  Leptomeningeal Metastases in the 7MM
• Total Treated Cases of Leptomeningeal Metastases in the 7MM

Download the report to understand which factors are driving Leptomeningeal Metastases epidemiology trends @ Leptomeningeal Metastases Epidemiological Insights

Recent Developments In The Leptomeningeal Metastases Treatment Landscape:

• In April 2025, the Phase I ReSPECT-LM trial of REYOBIQ (Rhenium Obisbemeda) for leptomeningeal metastases demonstrated a dose-dependent increase in drug delivery, reaching 253 Gy in Cohort 5. Neuroimaging results from 16 patients indicated a 31% partial response rate and a 75% clinical benefit rate, while physician evaluations in 14 patients reported a 14% response rate and an 86% clinical benefit.
• In February 2025, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, successfully establishing a recommended Phase 2 dose (RP2D).
• In December 2024, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, shared an update on its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for leptomeningeal disease (LM), with a particular emphasis on breast cancer patients.
• In February 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology firm focused on oncology, announced the early conclusion of a significant two-part Phase I trial due to positive safety results and encouraging clinical responses observed thus far. This investigator-initiated study assessed the use of paxalisib, an oral dual inhibitor of PI3K/mTOR, in conjunction with radiation therapy for treating patients with brain metastases from solid tumors that have PI3K pathway mutations.

Leptomeningeal Metastases Therapies and Key Companies

• MTD 217: Biodexa Pharmaceuticals
• Pemetrexed: Innovent Biologics (Suzhou) Co. Ltd.
• 186RNL: Plus Therapeutics
• Patritumab deruxtecan: MedSIR
• QBS72S: Quadriga Biosciences, Inc.
• REYOBIQ (Rhenium Re186 Obisbemeda): Plus Therapeutics
• 177Lu-DTPA-O Mburtamab Radioimmunotherapy: Y-mAbs Therapeutics
• Rhenium-186 NanoLiposome: Plus Therapeutics
• ANG1005: AngioChem

Discover more about therapies set to grab major Leptomeningeal Metastases market share @ Leptomeningeal Metastases Medications

Leptomeningeal Metastases Market Drivers

• Rising Incidence of Advanced Cancers: Increasing prevalence of breast cancer, lung cancer, and melanoma drives the risk of LM development.
• Advancements in Diagnostic Technologies: Improved imaging (MRI, PET-CT) and CSF cytology enhance early detection rates.
• Growing Awareness Among Physicians: Better recognition of LM symptoms leads to more timely interventions.
• Innovation in Targeted Therapies: Introduction of targeted therapies (e.g., EGFR inhibitors, HER2-targeted agents) and immunotherapies improves survival, increasing treatment adoption.
• Expansion of Personalized Medicine: Tailored treatment approaches based on tumor genetics and biomarkers boost market potential.

Leptomeningeal Metastases Market Barriers

• Limited Treatment Options: Leptomeningeal Metastases is challenging to treat due to the blood-brain barrier and poor drug penetration.
• Late Diagnosis: Symptoms are often nonspecific, leading to delayed detection and treatment.
• High Treatment Costs: Advanced therapies and diagnostic procedures can be expensive, limiting patient access.
• Poor Prognosis: Short median survival times reduce long-term treatment demand.
• Regulatory Challenges: Approval pathways for novel CNS-targeted therapies can be complex and time-consuming.

Scope of the Leptomeningeal Metastases Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain) and the United Kingdom, and Japan]
• Key Leptomeningeal Metastases Companies: Biodexa Pharmaceuticals, Innovent Biologics (Suzhou) Co. Ltd., Plus Therapeutics, MedSIR, Quadriga Biosciences, Inc., Plus Therapeutics, Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others
• Key Leptomeningeal Metastases Therapies: MTD 217, Pemetrexed, 186RNL, Patritumab deruxtecan, QBS72S, REYOBIQ (Rhenium Re186 Obisbemeda), 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Leptomeningeal Metastases Unmet Needs, KOL’s views, Analyst’s views, Leptomeningeal Metastases Market Access and Reimbursement 

To know more about Leptomeningeal Metastases treatment, visit @ Leptomeningeal Metastases Treatment Landscape